GLP1R and diabetic kidney disease: A combination of new therapies, namely SGLT2 inhibitors and GLP-1 receptor agonists, may positively contribute to individuals’ self-management abilities and glycemic control, leading to an improvement in renal outcomes, DKD experience and thus QoL.